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Aim: To investigate the expression of ABCC11 (MRP8) protein in normal breast tissue, and examine the difference in ABCC11 mRNA 
and protein expression between normal breast and breast cancer tissues taking into account ABCC11 genotype (a functional SNP, 
rs17822931) and estrogen receptor (ER) status. Methods: Sections of paraffin-embedded normal and malignant tissues from 
10 patients with invasive ductal carcinoma were used for immunohistochemical analysis. DNA and RNA were extracted from the 
same sections and used for genotyping and ABCC11 transcript expression measurement by quantitative RT-PCR. Results: A strong 
expression of ABCC11 was found in epithelial and myoepithelial cells of normal breast lobules and ducts in individuals with different 
ABCC11 genotypes. A predominant decrease of ABCC11 expression was observed in malignant tissue compared to normal beast 
specimen (8 of 10 cases), despite four out of ten tumors showed the elevated ABCC11 mRNA level as compared to the normal coun-
terpart. Neither ABCC11 mRNA nor protein expression in normal or cancerous tissue correlated with ER status. Conclusion: The 
expression of ABCC11 protein appears to be decreased in most BC. The effect of ABCC11 protein on breast cancer chemosensitivity 
is likely to be more complex than that which can be directly inferred from ABCC11 genotype and mRNA expression level in the tumor. 
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Human ATP-binding cassette (ABC) transport 
proteins have an essential function of extruding toxins 
from cells [1]. Namely this function brings ABC trans-
porters into the focus of the studies of multidrug re-
sistance of tumor cells. Starting with the ABCB1 gene 
product, MDR1, several other transporters have been 
shown to cause anti-cancer drug resistance in cell 
culture through an increased efflux and decreased 
intracellular accumulation of chemotherapeutic agent 
[2]. Most ABC transporters associated with tumor 
resistance belong to the ABCC subfamily. 
The ABCC11 gene product (also known as MRP8) 
is one of nine multidrug resistances (MDR)-associated 
proteins of the ABCC subfamily. ABCC11 substrates 
include cyclic nucleotides, monoanionic bile acids, 
steroid sulfates, estradiol 17-β-D-glucuronide [3–4]. 
ABCC11 has been proved to confer resistance to che-
motherapeutic drugs 5-fluorouracil (5-FU) [5] and 
pemetrexed (MTA, Alimta) [6]. 
Profiling of MDR proteins expression in cancer 
cells is an important direction in exploring of drug 
resistance mechanisms and discovering biomarkers 
of a particular tumor type. Breast cancer (BC), as the 
most common type of non-skin cancer in women and 
the fifth most common cause of cancer death, involves 
an intense research effort in this regard. Apart from 
MDR1 [7], no evidence has been reported yet on the 
relationship of ABC transporters with drug resistance 
of BC cells. At the same time, MDR genes transcripts, 
including ABCC11 mRNA, have been shown to be over-
expressed in BC [8–9]. Elevated expression levels 
of ABCC11 in estrogen receptor (ER)α-positive, as com-
pared to ERα-negative BC, were reported by Honorat 
et al. [10]. The authors also observed the regulation 
of the ABCC11expression by estrogen in MCF7 breast 
cancer cell line [10]. However, no studies addressing 
differential ABCC11 expression in normal and cancerous 
breast tissues have been done so far. Similarly, nothing 
currently is known about the ABCC11 protein expres-
sion in normal breast tissue in comparison to the tumor.
This work was set out to examine the ABCC11 tran-
script and ABCC11 protein expression in BC and 
matched normal breast specimens in 10 women in rela-
tion with ER status. We also analyzed ABCC11 expres-
sion levels with regard to a functional SNP (rs17822931) 
in the ABCC11 gene that apparently affects the trans-
port activity of the protein [11–14]. 
MATERIALS AND METHODS
Samples. The study protocol was approved by the 
Committee for the Ethical Issues of Human Genome 
and Gene Analysis of Health Sciences University of Hok-
kaido. A total of 10 BC and normal mammary gland 
specimens which were located away from the tumor 
of the same patient were selected from pathological 
archives of the Department of Molecular Pathology, 
Atomic Bomb Disease Institute, Nagasaki University, 
Japan. Clinicopathological information on BC samples 
including ER status (positive/negative, as a part of rou-
tine pathological diagnosis of BC) was obtained from 
patients’ records. Serial 5 �m sections of normal tissue 
and BC surgical specimen mounted on microscope 
slides were available for the study. Sections of all speci-
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mens were stained with hematoxylin and eosin and re-
analyzed by an experienced pathologist to confirm that 
each BC specimen contained cancerous tissue, and 
each normal breast sample was free of malignant tissue.
DNA extraction and genotyping. DNA was ex-
tracted from paraffin-embedded sections with DEXPAT 
reagent (TaKaRa Bio Inc., Otsu, Japan) according 
to the manufacturer’s protocol. DNA was further pre-
cipitated with ethanol, reconstituted in TE buffer and 
2 μl was used as a template in genotyping reactions. 
The samples were genotyped by TaqManTM assay using 
the reagents, primers and probes (Applied Biosystems 
by Life Technologies, Foster City, CA, USA) and thermal 
cycling conditions described in our recent work [15]. 
The assays were run in a Rotor-Gene Q (QIAGEN, 
Tokyo, Japan). Four replicates of each sample were 
analyzed. Genotypes were assessed by automated 
allelic discrimination analysis and by comparison with 
external controls with known genotypes.
Quantitative real-time (qRT)-PCR. RNA was 
extracted from FFPE sections mounted on micro-
scope slides with RNeasy FFPE kit (QIAGEN, Tokyo, 
Japan) according to the manufacturer’s protocol with 
additional 3 min incubations at 50 ºC after adding 
of 1 ml of xylene, and before the first centrifugation 
step. cDNA was then synthesized using SuperScript 
First-Strand Synthesis System for RT-PCR (Invitrogen, 
Carlsbad, CA, USA). Three independent reverse-
transcription reactions were done for each sample, 
and the content of each of the three tubes was used 
as an individual template in triplicate qRT-PCR. Com-
mercially available TaqMan® Gene Expression Assays 
(Applied Biosystems by Life Technologies, Foster City, 
CA, USA) were used to analyze the target (ABCC11 and 
ESR1) and reference cDNAs (MRLP19, TBP, TFRC). 
The respective assay IDs are listed in Table.
Table. Gene Expression Assays used as primers for quantitative RT-PCR
Gene symbol Assay ID
ABCC11 Hs01090769_m1
ESR1 Hs00174860_m1
MRLP19 Hs00608522_m1
TBP Hs00427621_m1
TFRC Hs00951083_m1
Note: Assays were purchased from Applied Biosystems by Life Technolo-
gies (Foster City, CA, USA).
MRLP19, TBP and TFRC were selected as refer-
ence genes for normalization according to Drury et al. 
[16], who found these to be particularly suitable for 
gene expression analysis in FFPE material. To meet 
another important condition for qRT-PCR of FFPE 
samples [17], expression assays for all genes were 
selected to amplify the target as close to the 3’ end 
as possible. To comply with the MIQE Guidelines [18], 
each set of primers was tested for efficacy using se-
rial dilutions of a control cDNA sample. Reaction was 
performed in TaqMan® Universal PCR Master Mix 
(Applied Biosystems by Life Technologies, Foster City, 
CA, USA) under the following thermal profile: after the 
initial incubation at 50 ºC for 2 min followed by 95 ºC for 
10 min, reaction was cycled 55 times at 95 ºC for 15 sec 
and at 60 ºC for 1 min in a Rotor-Gene Q machine. Geo-
metrical mean of the relative concentrations of ABC-
C11and ESR1 against each of MRLP19, TBP, and TFRC 
was used as the expression index in further analysis. 
Antibodies. The ERα was detected in human 
breast tissues with a mouse monoclonal antibody 
NCL-ER-6F11 (Novocastra Laboratories, Newcastle, 
UK) diluted 1:80. ABCC11 was detected with rabbit 
polyclonal antibody provided by Dr. K.Yoshiura at the 
dilution of 1:100. For the immunofluorescent detection 
of the proteins, we used secondary anti-mouse –Alexa 
Fluor 594 and anti-rabbit –Alexa Fluor 488 (Invitrogen, 
Carlsbad, CA, USA) conjugates at 1:200 dilution. All 
antibodies were diluted in 1% BSA (Sigma, St Louis, 
MO, USA) in 0.01M PBS. 
Immunohistochemical double labeling for 
ER and ABCC11. Sections of paraffin-embedded tis-
sues were mounted on aminoalkylsilane-coated slides, 
deparaffinized, and rehydrated. The sections were se-
quentially incubated in four changes of boiling 0.01 M ci-
trate buffer, pH 6.0, 5 min each, 2% hydrogen peroxide 
at room temperature for 15 min, three changes of PBS, 
5 min each, and in 5% BSA blocking solution at room 
temperature for 20 min. Then the slides were washed 
in PBS for 10 min and incubated overnight at 4 °C in the 
mixture of primary anti-ER and anti-ABCC11 antibodies 
diluted as described above. After incubation the sec-
tions were washed in three changes of PBS, 10 min 
each, followed by 30 min incubation at room tempera-
ture with the mixture of the secondary antibodies. The 
slides were then rinsed in four changes of PBS, covered 
with Vectashield H-1200/DAPI mounting media (Vector 
Laboratories, Burlingame, CA, USA) and analyzed under 
a Biorevo BZ-9000 (Keyence Corp., Woodcliff Lake, NJ, 
USA) fluorescent microscope. The three-color images 
were acquired, merged and processed to remove haze 
and adjust the background using the built-in software. 
Green fluorescence intensity (ABCC11) was measured 
in the images and normalized to blue fluorescence in-
tensity (nuclei) using Image-Pro software (v.4.5, Media 
Cybernetics, Bethesda, MD, USA).
RESULTS
Localization of ABCC11 in normal breast tis-
sue. The localization of the ABCC11 protein product 
in normal breast lobules and terminal ducts was 
determined by immunochistochemistry. The high 
level of ABCC11 expression was seen in all 10 speci-
mens (Fig. 1, 1N-10N). As shown in Fig. 1-3N, the 
ABCC11 protein was detected within the layer of both 
luminal epithelial (Fig.1-3N, hollow arrow) and basal 
myoepithelial cells (Fig. 1-3N, solid arrow). Of note, 
normal mammary cells appear to express ABCC11 re-
gardless of the rs178829931 genotype or ER status. 
Expression of ABCC11 mRNA. We compared 
ABCC11 transcript levels in normal breast tissues and 
in tumors. As shown in Fig. 2, the increased ABCC11 ex-
pression in cancerous tissue was seen in 4 of 10 pa-
tients (Patients 1, 6, 7, and 10). In six patients, the 
decreased expression as compared to normal breast 
was observed. The changes in ABCC11 expression 
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were irrelevant to the tumor ER status (the obtained 
ER staining results perfectly corresponded to those 
in patients’ medical records in all cases) or 538G > A 
(rs178829931) polymorphism. Moreover, no correla-
tion was found between ABCC11 and ESR1 expression 
in tumors (Pearson’s correlation coefficient, r = 0.175) 
or in normal breast tissue (r = -0.182). 
Expression of ABCC11 in BC. IHC analysis revealed 
an evident decrease in ABCC11 expression in tumor tis-
sues in 8 patients as compared to the normal counterpart 
(Fig. 1, 1C–5C, 7C, 9C, and 10C). The quantification 
of green fluorescence intensity revealed 1.8- to 6.7-fold 
decrease of the signal (Fig. 3). ABCC11 levels in the 
remaining two BC samples were comparable to those 
in normal tissue (Fig. 1, 6C, 8C), 1.17- to 1.39-fold sig-
nal fading (see Fig. 3). Thus, none of examined tumor 
samples showed ABCC11 over-expression as compared 
to normal breast. Interestingly, in three BC samples a very 
low protein expression was detected despite the high 
mRNA levels (Fig. 1, 1C, 9C, and 10C). 
DISCUSSION
In the present study we found a predominant 
decrease of the ABCC11 product, ABCC11 protein, 
expression in BC as compared to the normal breast 
tissue of the same patient, and such decrease did not 
correlate with ABCC11 mRNA level. Only two of ten 
BC specimens displayed ABCC11 expression similar 
to that in the normal tissue.
The function of ABCC-subfamily transporters and 
their role in tumor resistance are intensively investigat-
ed. ABCC11 mRNA expression data are also available 
from rather numerous BC analyses. Several studies 
reported ABCC11 mRNA over-expression in BC tissue 
and BC cell lines [8–9, 19–20]. Park et al. [19] observed 
the increased expression of ABCC11 in BC patients 
with residual disease compared to those who achieved 
a complete response, although the authors did not 
include ABCC11 in their optimal molecular prognosti-
cator of BC response to neoadjuvant chemotherapy. 
Honorat et al. [10] pointed at the possibility of estrogen 
involvement in the regulation of ABCC11 expression. 
On the other hand, estrogen-responsive genes have 
been implicated in acquired resistance to tamoxifen 
or aromatase inhibitors [21]. Taken together, the 
existing knowledge on ABCC11 expression in BC indi-
cates that this protein may play a role in the regulation 
of chemotherapy response.
Most studies of tumor resistance are performed 
using cell cultures. However, the origin of cells used 
to establish cell lines does not represent all tumor types 
and the conditions of cell culturing appear to limit trans-
lational application of the results obtained in cell lines. 
Our results show that in a real tissue, ABCC11 mRNA 
level poorly correlates with protein expression. This find-
ing emphasizes the importance of parallel examination 
of ABCC11 mRNA and protein product in normal and 
malignant breast tissue. As we demonstrated, surgical 
samples stored as FFPE tissues could be successfully 
used for such an analysis.
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 Fig. 1. Expression of ABCC11 and ERα in normal mammary (N, 
left column) and breast cancer (C, right column) tissues of 10 pa-
tients. The ABCC11 protein (green) and the ESR1 protein (red) 
were detected on 5 μm FFPE sections and merged as described 
in Materials and Methods. The DAPI counterstaining of the nuclei 
appears in blue. The genotype at rs17822931 of each patient 
is indicated on the right of each normal-cancer image pair 
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Fig. 2. Expression of ABCC11 and ESR1 transcripts in normal 
mammary tissue and breast cancer tissue of 10 patients. Expres-
sion was measured by qRT-PCR, and the geometrical mean 
of ABCC11 and ESR1 relative concentrations against three refer-
ence genes was used as an estimate of gene expression level. 
Black diamonds represent the ratio of ABCC11 mRNA expression 
level in BC to that in normal tissue. Circles represent the changes 
in ESR1 mRNA expression 
0,0
0,5
1,0
1,5
2,0
2,5
ER +
C
Re
la
tiv
e 
AB
CC
11
 le
ve
l
  AA
  GA, GG
N CN
ER -
Fig. 3. Down-regulation of ABCC11 protein in BC tissues. The 
relative intensity of green signal was determined in normal and 
malignant tissue images as described in Materials and Methods. 
The decrease of ABCC11 fluorescence intensity from normal (N) 
to cancer (C) tissue was observed in each patient irrespectively 
of ER status or genotype
To better understand the role of ABCC11 in BC, the 
knowledge of protein localization in normal mammary 
gland is essential. Our experiments employing immuno-
histochemical staining demonstrated that ABCC11 is ex-
pressed in epithelial and myoepithelial cells of breast lob-
ules and ducts. The presence of ABCC11 in epithelial cells 
of normal terminal duct lobular unit (TDLU), the structural 
and functional unit of the breast, implies the involvement 
of this transporter in secretion function of the mammary 
gland, and is consistent with the finding that the volume 
of colostrum secretion depends on ABCC11 genotype 
at rs17822931 [12]. Of interest is the observation that 
ABCC11 is expressed also in myoepithelial cells which 
do not express ERα [22]. Our examination of ABCC11 lo-
calization may suggest that the protein participates not 
only in apocrine secretion, but also in metabolite trans-
port into the stroma embedding ducts and lobules.
Transport activity of ABCC11 is strongly affected 
by a SNP at nucleotide 538 (538G > A, rs17822931) 
of ABCC11 [14]. This SNP determines human earwax 
type, and associates with some functions of apocrine 
glands. Individuals with the AA genotype are character-
ized by the reduced cerumenous secretion [14] and 
a nearly complete loss of axillary odor [11] as compared 
to those homozygous or heterozygous for wild-type 
G allele. However, as the results reported here reveal, 
the ABCC11 polymorphism does not seem to influence 
the localization of the ABCC11 protein in the mammary 
gland. The ABCC11 expression pattern was similar in the 
mammary glands of different ABCC11 genotype carriers, 
suggesting that non-functional ABCC11 is not degraded 
but incorporated into the cellular membrane. Similar 
observations were previously made in the sweat glands 
[11]. Although ABCC11 expression in normal breast 
or BC is independent of rs17822931, functional studies 
of the ABCC11 SNP are potentially useful. This could be il-
lustrated by the study of the ABCC11 role in lung cancer 
cell resistance to MTA, in which ABCC11 expression level 
did not correlate with IC50 for MTA; yet ABCC11 genotype 
affected chemosensitivity [6]. 
In conclusion, the expression of ABCC11 protein which 
localizes in epithelial and myoepithelial cells of normal 
breast lobules and ducts is likely to be decreased in the 
majority of BC or it may be comparable to that in normal 
tissue in some cases. It remains to be elucidated whether 
ABCC11 loss or retention in BC is functionally relevant 
to tumor development or may affect clinical course and 
prognosis. Therefore, further studies of ABCC11 expres-
sion in BC are warranted to determine its usefulness for 
decision making on BC therapy protocol.
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